Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review
Safety Any serious adverse event · adults with fibromyalgia
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether radix Sophorae flavescentis changes proportion of participants with 1 or more adverse events considered… compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Safety Any serious adverse event · patients with fibromyalgia
It is very uncertain whether serotonin noradrenaline reuptake inhibitors changes safety (serious adverse events) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in serious adverse events by week 8 compared with placebo (low certainty).
1 finding from 1 review
Serious or severe adverse events · people with diabetes and orthostatic hypotension
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of serious adverse events · patients with osteoarthritis
Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.92 [0.14, 6.21]
669 participants
Moderate
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by 6 weeks · people with agitation in dementia
It is very uncertain whether valproate preparations changes serious adverse events by 6 weeks compared with placebo (very low certainty).
1 finding from 1 review
Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review